All In Biotech

Drug Trial Radar · NCT03171142

Effect of Heliox on RSV Bronchiolitis

Effect of Heliox on Infants With Respiratory Syncytial Virus Acute Bronchiolitis-A Revisit Study

Last checked: Nov 19, 2026Latest source record: May 31, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 104 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

104

Actual

Start

May 1, 2015

Primary completion

Aug 1, 2016

Study completion May 1, 2017

Sponsor

Lead sponsor
Wael SeliemAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 31, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 1 month, up to 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Helium is an inert gas with a density almost one-seventh of that of air. Based on its properties breathing a mixture of helium and oxygen (heliox) will lead to a reduction in resistance through narrowed airways and consequently decreases the work of breathing. Participating infants with RSV acute bronchiolitis will be supplied with heliox (ration of 21 oxygen and 79 helium) delivered through a flow nasal cannula to evaluate heliox effect in improving their oxygenation. Heliox will act as an additive therapy to improve oxygenation in patients with lower respiratory tract infection caused by respiratory Syncytial Virus (RSV) and will decrease the need for more complicated therapies.

Conditions

  • RSV Infection
  • Acute Bronchiolitis

Interventions

  • HelioxDrug

    Heliox (21:79) via nasal cannula 2 litter per minutes

  • AirDrug

    Air 21% via nasal cannula 2 litter per minutes

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Improvement in oxygenationTime frame: change from baseline at 24 hours after treatment

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.